NCT00405301View on ClinicalTrials.gov

Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage

PHASE4CompletedINTERVENTIONAL

Enrollment

175

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

December 31, 2008

Conditions

Drug Induced HepatotoxicityTuberculosis

Interventions

DRUG

Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)

Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.

Trial Locations (2)

110029

All India Institute of Medical Sciences, New Delhi

517507

Sri Venkateswara Institute of Medical Sciences, Tirupati

All Listed Sponsors

lead

All India Institute of Medical Sciences

OTHER

NCT00405301 - Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage | Biotech Hunter | Biotech Hunter